Calcifediol

ALIMENTARY TRACT AND METABOLISM

Key facts

Calcifediol is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1980. DrugCentral lists 3 molecular targets, including Vdr, SREBF1 and VDR. Recorded indications include Hypocalcemia, Hypophosphatemia, Renal osteodystrophy and Rickets.

• Approval status: ofp (first approved 1980 by the FDA).
• Molecular targets: Vdr, SREBF1 and VDR (3 listed in DrugCentral).
• Indications: Hypocalcemia, Hypophosphatemia, Renal osteodystrophy and Rickets.
• ATC code: A11CC06 (Vitamin D and analogues).
• Molecular formula: C27H44O2; molecular weight 400.65 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Hypocalcemia
• Hypophosphatemia
• Renal osteodystrophy
• Rickets

Off-label uses (1)

• Vitamin D deficiency

Contraindications (7)

• Arteriosclerosis obliterans
• Hypercalcemia
• Hyperphosphatemia
• Hypervitaminosis D
• Kidney disease
• Kidney stone
• Sarcoidosis

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Vitamin D3 receptor	Vdr	unknown	EC50 6.22
Sterol regulatory element-binding protein 1	SREBF1	unknown	IC50 5.93
Vitamin D3 receptor	VDR	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1980-08-05	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
A11CC06	ALIMENTARY TRACT AND METABOLISM › VITAMINS › VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO › Vitamin D and analogues
H05BX05	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CALCIUM HOMEOSTASIS › ANTI-PARATHYROID AGENTS › Other anti-parathyroid agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug interaction	124.3
Death	123.0
Acute kidney injury	78.9
Thoracic vertebral fracture	65.8
Plasma cell myeloma refractory	63.2
Dialysis	63.0
Hyponatraemia	53.8
COVID-19	47.2
Hospitalisation	45.1
Hypervitaminosis D	40.9
Sopor	39.7
Hypertransaminasaemia	37.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Calcifediol is on its molecule page.

• Molecular formula: C₂₇H₄₄O₂
• Molecular weight: 400.65 g/mol
• CAS number: 19356-17-3
• InChIKey: JWUBBDSIWDLEOM-DTOXIADCSA-N
• PubChem CID: 5283731

C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Calcifediol used for?

DrugCentral lists the following indications for Calcifediol: Hypocalcemia, Hypophosphatemia, Renal osteodystrophy and Rickets.

How does Calcifediol work?

Its molecular targets in DrugCentral include Vdr, SREBF1 and VDR (agonist).

When was Calcifediol first approved?

Calcifediol was first approved by the FDA in 1980.

What is the chemical formula of Calcifediol?

Calcifediol has the molecular formula C27H44O2 and a molecular weight of 400.65 g/mol.

Sources

• DrugCentral drug card 464 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3544909 — compound record and bioactivity
• PubChem CID 5283731 — chemical identifiers
• DrugBank DB00146 — drug record
• FDA UNII P6YZ13C99Q — substance identity
• DailyMed: FDA labels for Calcifediol — current prescribing information (label search)
• UniProt P36956 (SREBF1) — target protein
• UniProt P11473 (VDR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.